



www.heartuk.org.uk/conference

35th Annual Medical & Scientific Conference  
**Lipids - one huge step for healthcare?**  
 Oculus Building, University of Warwick, Coventry  
 Wednesday 6 - Friday 8 July 2022



**Keynote Myant lecture - Frederick Raal (Johannesburg)**

**REGISTRATION IS OPEN**

## Lipids - one huge step for healthcare?

### PROGRAMME

#### Tuesday 5 July

TIME	TOPIC	SPEAKER	LOCATION
16:00 – 18:30	<b>HEART UK Board meeting</b>	Hosted by: Jules PAYNE	Radcliffe House - Mtg space 37 - 1st floor
16:00 – 22:00	<i>EXHIBITION BUILD</i>		Oculus foyer
18:45 - 19:15	<b>HEART UK - meet the team</b> ( <i>invited guests only</i> )	Hosted by: Jules PAYNE	Radcliffe House lounge area - ground floor
19:30	<b>HEART UK + informal speaker dinner</b> ( <i>invited guests only</i> )	Hosted by: Jules PAYNE	Radcliffe House private dining room

#### Wednesday 6 July

TIME	TOPIC	SPEAKER / HOST	LOCATION
07:00 - 09:00	Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:30	Registration opens		Oculus foyer
09:00 - 11:00	<b>HEART UK MS&amp;R Committee meeting</b>	Chair - Prof Handrean SORAN	Oculus room OC 1.01 - 1st floor
11:00 - 11:15	Comfort break		
11:15 - 12:30	<b>Lipid Interest group meeting</b>	Chair - Alison POTTLE	Oculus room OC 0.02 - grnd floor
11:00 - 12:30	Registration   Networking   Exhibition		Oculus foyer
11:45 - 12:30	Lunch		Oculus foyer
12:30 - 12:40	<b>Chairman's Welcome</b> Celebrating 20 years since the BHA/FHA merger	<b>Dr Peter GREEN</b>	Oculus LT 1.05 - 1st floor
	<b>SESSION ONE</b>		
	Co-chairs: <b>Peter PENSON</b> + <b>Michaela NUTTALL</b>		

12:40 - 13:05	<b>Plenary speaker</b> <b>Tackling Cholesterol Together - The Role of Pharmacy &amp; New Therapeutic Options</b> Pharmacy Role in Tackling Hyperlipidaemia & New Therapeutic Options	<b>Dr Rani KHATIB</b> (Leeds, UK)	Oculus LT 1.05 - 1st floor
13:05 - 13:15	Discussion		
13:15 - 13:40	<b>Plenary speaker</b> <b>CVD risk and gender reassignment</b> Gender reassignment therapy has been associated with elevated triglyceride concentrations, often accompanied by an increase in high density lipoprotein levels, reduced circulating homocysteine (Hcy), uric acid and creatinine levels as well as an adverse effect on glycaemic control. Therefore, vascular risk factor screening and potential intervention may be required prior to and during gender reassignment therapy (both hormone and surgical).	<b>Dr Devi NAIR</b> (London, UK)	Oculus LT 1.05 - 1st floor
13:40 - 13:50	Discussion		
13:50 - 14:20	Refreshments   Networking   Exhibition		Oculus foyer
	<b>SESSION TWO - Fats v Carbs in Lipid Management - the Controversy</b>		
	<b>Chair: Alan FLANAGAN</b>		
14:20 - 15:20	<b>Plenary speaker</b> <b>Fats versus carbs in lipid management - the controversy: Evidence for fats and carbs</b> In contrast to controversy, there is now clear consensus on the amount and quality of dietary fat and carbohydrate for the management of blood lipids. Controversy has arisen over the effects of extreme diets which exclude one of these macro-nutrients. While there is consistent evidence that this dietary approach can help to promote weight loss and improve weight-related biomarkers of cardiovascular risk, an important and outstanding question is whether high fat, low carb diets carry potential for adverse effects on blood cholesterol?	<b>Prof Bruce GRIFFIN</b> (Surrey, UK)	Oculus LT 1.05 - 1st floor
15:20 - 15:30	Discussion		
15:30 - 16:00	Refreshments   Networking   Exhibition		Oculus foyer
	<b>SESSION THREE - sponsored symposia</b>		
16:00 - 16:40	<b>Symposia session 1</b>  <b>New approaches and innovation in lipid services – 2022 and beyond</b> <b>Chair: Dr. Adie Viljoen</b>  <b>Session 1: Innovative, centralised multidisciplinary medicines optimisation clinic for PCSK9 inhibitors - Dr. Rani Khatib</b> <b>Session 2: LOSP project and using innovative tools for case finding – Dr. Stewart Pattman / Dr Catherine Tucker</b>  <i>This symposium is intended for UK Healthcare Professionals only</i>	<b>Dr Rani KHATIB</b> <b>Dr Stewart PATTMAN</b> <b>Dr Catherine TUCKER</b>	Oculus LT 0.03 - ground floor
16:40 - 16:50	<b>Sponsored by Sanofi</b> Changeoever		

16:50 - 17:30	<p><b>Symposia session 2</b></p> <p><b>What more can we do to optimise lipid management in your patients experiencing statin intolerance</b> This sponsored promotional symposium is organised by Daiichi Sankyo UK. The speaker faculty will discuss the clinical management of patients with elevated cholesterol intolerant to statin therapy.</p> <p><i>This symposium is intended for UK Healthcare Professionals only</i></p> <p><b>Sponsored by Daiichi-Sankyo</b></p>	<p><b>Dr Yassir JAVAID</b>, Cardiology GPSI and Clinical lead for Cardiology East Midlands Clinical Network</p> <p><b>Professor Sudarshan RAMACHANDRAN</b>, Consultant Chemical Pathologist, University Hospitals Birmingham / University Hospitals of North Midlands</p>	Oculus LT 0.03 - ground floor
17:30 - 18:30	Break - check into accommodation		
17:30 - 18:00	<b>HEART UK AGM</b>	Chair - Jules Payne	Oculus LT 1.05 - 1st floor
18:30 - 19:10	<b>FH nurses + pharmacy informal networking session</b>	FH Nurse host: Lisa Griztmacher Pharmacist host: Catherine Tucker	Oculus - 1st floor landing
18:30 - 21:30	<b>Welcome reception and buffet reception</b>		Oculus foyer
19:30:00	Chairman's welcome   <a href="#">Dr Pete Green</a> Premium sponsor welcome   <a href="#">Debbie Woods</a> (Head of Medical, UK and Ireland, General Medicines, Sanofi) Presentation of the Rianna Wingett award by <a href="#">Dr Alan Rees</a>		
21:30:00	Evening ends		

## Thursday 7 July

TIME	TOPIC	SPEAKER / HOST	LOCATION
07:00 - 09:00	Breakfast ( <i>Bluebell House residential guests only</i> )		Rootes Building - 1st floor restaurant
08:00 - 09:00	<b>Healthcare committee meeting</b>	Hosted by: Michaela Nuttall	Oculus room OC 1.01 - 1st floor
08:30	Registration opens		Oculus foyer
08:30 - 09:20	Refreshments   Networking   Exhibition		Oculus foyer
08:45 - 09:15	<b>Pharmacy networking meeting</b>	Hosted by: Catherine Tucker	Oculus 1.03 - 1st floor
09:20 - 09:25	<b>Opening remarks</b>	<b>Dr Nigel CAPPS</b>	Oculus LT 1.05 - 1st floor
	<b>SESSION FOUR</b>		
	Co-chairs: <a href="#">Sara JENKS</a> + <a href="#">Kate SHIPMAN</a>		
09:25 - 09:50	<p><b>Plenary speaker</b></p> <p><b>Statin myopathy and myositis</b> To provide a background about adverse events related to statins and the spectrum of associated muscle involvement.</p>	<b>Prof Hector CHINOY</b> (Manchester, UK)	Oculus LT 1.05 - 1st floor
09:50 - 10:00	Discussion		

10:00 - 10:25	<p><b>Plenary speaker</b>  <b>The role of non-invasive CT coronary angiography in the Lipid Clinic</b>  An overview of the past, current and future CT technologies that non-invasively assess for coronary artery disease and how they can impact the clinical management of high risk asymptomatic patients with lipid disorders.</p>	Dr Jonathan C. L. RODRIGUES (Bath, UK)	Oculus LT 1.05 - 1st floor
10:25 - 10:35	Discussion		
10:35 - 11:05	Refreshments   Networking   Exhibition		
	<b>SESSION FIVE</b>		
11:05 - 12:15	<p><b>Lipids - Devolution Differences</b>  A discussion of the varied approaches to diagnosis and management in different parts of the United Kingdom  Hear representative views from England, N Ireland, Scotland and Wales.</p>	Facilitator/Chair - Ian MCDOWELL (Cardiff, UK) England   Kate SHIPMAN (Chichester, UK) N Ireland   Paul HAMILTON (Belfast, UK) Scotland   Sara JENKS (NHS Lothian, UK) Wales   Yee Ping TEOH (Wales, UK)	Oculus LT 1.05 - 1st floor
12:15 - 13:30	Lunch   Networking   Exhibition		Oculus foyer
12:15 - 13:30	<b>Simon Broome committee meeting</b>	Hosted by: Nigel Capps	Oculus room OC 1.01 - 1st floor
12:30 - 12:50	<p><b>Meet the Expert Taster session 1:</b>  <b>Pill Swallowing</b>  Discussing the barriers to medication adherence as a result of difficulties taking lipid-lowering medicines.</p>	Dr Alice MCCLOSKEY (Liverpool, UK)	Oculus mtg OC 0.02 - grnd floor
12:50 - 12:55	Break		
12:40 - 12:50	Premium sponsor "Meet the expert" Hosted in the Sanofi stand	Dr Rani KHATIB (Leeds, UK)	Sanofi stand
12:55 - 13:15	<p><b>Meet the Expert Taster session 2:</b>  <b>Careers in Lipidology</b>  What career pathways do we currently have in lipids and what developments would we like to see in future for careers in lipids.    Nurses and Allied Health Care professionals are taking ever more responsibility for the care of patients within the NHS, including in specialist roles and Advanced Practice. Whilst career paths in clinical medicine are clearly defined and structured, this is not always the case for other healthcare professionals. In this we will consider what career paths exist for healthcare professionals in the field of lipids, and how these relate to qualifications and credentialling. We will facilitate a discussion about what changes may be needed to achieve more structured career progression, and to make more effective use of the skills and experience of nurses in lipidology.</p>	Ms Lisa GRITZMACHER (Bristol, UK) Prof Elizabeth HUGHES (Sandwell, UK) Dr Peter PENSON (Liverpool, UK)	Oculus mtg OC 0.02 - grnd floor
	<b>SESSION SIX - Lp(a)</b>		
	Co-chairs: Mike KHAN + Dermot NEELY		

13:30 - 14:00	<b>Plenary speaker</b> <b>Lipoprotein(a): Cardiovascular Risk and Emerging Therapies</b> This lecture will provide the latest updates on Lp(a) biology and clinical trials of Lp(a) lowering	<b>Prof Sotirios (Sam) TSIMIKAS</b> (San Diego, USA)	Oculus LT 1.05 - 1st floor
14:00 - 14:10	Discussion		
14:10 - 14:35	<b>Plenary speaker</b> <b>State of the nation - UK view on Lp(a)</b> Presentation of the findings of a recent survey performed by HEART UK of lipid clinics and clinical biochemistry laboratories to understand the availability, methodology and application of lipoprotein(a) measurement in the UK.	<b>Dr Jai CEGLA</b> (London, UK)	Oculus LT 1.05 - 1st floor
14:35 - 14:45	Discussion		
14:45 - 15:30	Refreshments   Networking   Exhibition		Oculus foyer
	<b>SESSION SEVEN</b> <b>Abstracts of free communications   Medical &amp; Scientific</b> Oculus LT 1.05 - 1st floor	<b>SESSION SEVEN</b> <b>Abstracts of free communications   Primary &amp; Healthcare</b> Oculus LT 0.03 - ground floor	
	Co-chairs: <b>Gordon FERNS + Yee Ping TEOH</b>	Co-chairs: <b>Elizabeth HUGHES + Alison POTTLE</b>	
15:30 - 15:40	<b>FC 1</b> <b>Lomitapide in the long-term real-world management of HoFH – effectiveness, tolerability, and hepatic safety from the Pan-European study</b> <b>Jai Cegla</b> (London, UK)	<b>FC 6</b> <b>Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records</b> <b>Barbara Iyen</b> (Nottingham, UK)	
15:40 - 15:45	Discussion	Discussion	
15:45 - 15:55	<b>FC 2</b> <b>Posttranscriptional regulation of the LDL Receptor in humans by the U2-spliceosome and its interactors</b> <b>Marta Futema</b> (London, UK)	<b>FC 7</b> <b>Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank</b> <b>Jasmine Gratton</b> (London, UK)	
15:55 - 16:00	Discussion	Discussion	
16:00 - 16:10	<b>FC 3 -</b> <b>The effect of adjusting LDL-cholesterol for Lipoprotein(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia</b> <b>Ben Jones</b> (London, UK)	<b>FC 8</b> <b>Familial Hypercholesterolaemia - a targeted Next Generation Sequencing panel and retrospective analysis of patients with no previously identified pathogenic variant</b> <b>Eloise Willis</b> (Cardiff, UK)	
16:10 - 16:15	Discussion	Discussion	
16:15 - 16:25	<b>FC 4</b> <b>Lipoprotein apheresis reduces SARS-CoV-2 S protein antibody levels in patients with familial hypercholesterolaemia after vaccination with BNT162b2</b> <b>Rajalakshmi Valaiyapathi</b> (London, UK)	<b>FC 9</b> <b>The potential cost-effectiveness of screening algorithms for familial hypercholesterolemia in primary care</b> <b>Steve E Humphries</b> (London, UK)	
16:25 - 16:30	Discussion	Discussion	
16:30 - 16:40	<b>FC 5</b> <b>Low-density lipoprotein receptor-negative compound heterozygous familial hypercholesterolaemia: case study with follow-up over 23 years</b> <b>Charles van Heyningen</b> (Liverpool, UK)	<b>FC 10</b> <b>How should high cholesterol, mutation negative children, identified through the child-parent screening project be managed?</b> <b>Lorraine Priestley-Barnham</b> (Harefield, UK)	
16:40 - 16:45	Discussion	Discussion	

16:45 - 17:05	Refreshments   Networking   Exhibition		Oculus foyer
	<b>SESSION EIGHT</b>		
	Chair: <a href="#">Handrean SORAN</a>		
	<b>Keynote Myant lecture:</b> <b>Severe familial hypercholesterolaemia – from a lethal disorder in childhood to a manageable dyslipidaemia today</b> Overcoming the challenges of severe FH has been a long and difficult journey, but with the treatment options now available, the future for severe FH looks bright.	<a href="#">Prof Frederick RAAL</a> (Johannesburg, South Africa)	
17:05 - 18:05			Oculus LT 1.05 - 1st floor
18:05 - 18:10	Day two closing remarks		
19:00 - 19:30	Pre dinner drinks reception		Panorama Suite - Rootes Building
19:30 - 23:30	Conference dinner		Panorama Suite - Rootes Building



## Friday 8 July

TIME	TOPIC	SPEAKER / HOST	LOCATION
07:00 - 09:00	Breakfast (Bluebell House residential guests only)		Rootes Building - 1st floor restaurant
08:30	Registration opens		Oculus foyer
08:00 - 09:00	<b>Apheresis Working Group committee meeting</b>	Chaired by: Dev Datta	Oculus room OC 0.02 - grnd floor
08:30 - 09:30	Refreshments   Networking   Exhibition		Oculus foyer
09:00 - 10:00	<b>Spotlight on posters session</b>		Oculus first floor landng
	<b>Moderated</b>		
	Judges   <a href="#">Frederick RAAL</a> , <a href="#">Alan REES</a> , <a href="#">Jai CEGLA</a> , <a href="#">Kate SHIPMAN</a>		
	1 <b>Development of a novel secondary care lipid e-referral pathway within Gloucestershire Hospitals NHS Foundation Trust</b> <a href="#">Kylie Beale</a> (Gloucester, UK)		
	2 <b>Assessment of GENinCode in the Diagnosis of Patients with Suspected Familial Hypercholesterolaemia</b> <a href="#">Peter E Carey</a> (Sunderland, UK)		
	3 <b>A primary Care based Familial Hypercholesterolaemia screening service in Guernsey, from concept to delivery</b> <a href="#">Matt Dorrian</a> (Guernsey, UK)		
	4 <b>Effect of SLCO1B1 genotypes on statin intolerance and response</b> <a href="#">Rahul Ghelani</a> (Harefield, UK)		
	5 <b>Low carbohydrate ketogenic diets as a cause of markedly elevated low-density lipoprotein cholesterol</b> <a href="#">Laura Hancox</a> (Bristol, UK)		
	6 <b>I used to dream that my cholesterol could be in single figures, and now it is!!!</b> <a href="#">Alison Pottle</a> (London, UK)		
	7 <b>A pharmacist-led remote model for identification and optimisation of Familial Hypercholesterolaemia patients in primary care</b> <a href="#">Charlotte Scott</a> (Tyne & Wear, UK)		

	How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused the APOB p.(Arg3527Trp) variant in a South Asian family	
8	<a href="#">Inessa Tracey</a> (West Bromwich, UK)	
	An outreaching lipid clinic model supporting PCSKgi uptake and lipid optimisation in secondary prevention across primary/secondary care interface	
9	<a href="#">Catherine Tucker</a> (North Sheilds, UK)	
	An investigation into any correlation between Single Nucleotide Polymorphism (SNP) score and Welsh score in Familial Hypercholesterolaemia patients and those with polygenic hypercholesterolaemia	
10	<a href="#">Jillian Webster</a> (Huddersfield, UK)	
	<b>Unmoderated</b>	
	Systematic vs opportunistic identification of familial hypercholesterolaemia in Malaysian primary care: a before and after study	
11	<a href="#">Hasidah Abdul-Hamid</a> (Nottingham, UK)	
	In An Ever-Changing World, Communication is Key	
12	<a href="#">Charis Browne</a> (London, UK)	
	Exploring the lived experience of being diagnosed with genetically confirmed familial hypercholesterolaemia in childhood	
13	<a href="#">Charis Browne</a> (London, UK)	
	FH Case Finding: A Multidisciplinary Review Post Cardiac intervention Patients in a NHS Trust between June 2019 and June 2021	
14	<a href="#">Eimear Connell</a> (Sunderland, UK)	
	How prepared are hairdressing salons and GP practices for working in partnership to promote the uptake of cardiovascular disease screening among women living in London's deprived and ethnically dense communities?	
15	<a href="#">Tethi Patel</a> (London, UK)	
	An ounce of prevention is worth a pound of cure', Harefield Familial Hypercholesterolaemia Service - Past Present and Future	
16	<a href="#">Lorraine Priestley-Barnham</a> (Harefield, UK)	
	Lipoprotein Apheresis: Delivering and Sustaining a Service Throughout the COVID-19 Global Pandemic	
17	<a href="#">Jo Senior</a> (London, UK)	
	Diagnosing Familial Hypercholesterolaemia (FH) as an additional finding from taking part in the 100,000 genomes project, the Wessex experience	
18	<a href="#">Catherine Sherman</a> (Southampton, UK)	
	Cascade screening for lipoprotein (a); controversies and guidance	
19	<a href="#">Kate Shipman</a> (London, UK)	
	NHS North Thames Genomic Medicine Service Alliance (NHS NTGMSA) Pilot: Implementing UCLPartners Proactive Care Framework for Familial Hypercholesterolaemia Screening and Cascade Testing in Primary Care	
20	<a href="#">Dominic Studart</a> (London, UK)	
10:00 - 10:10	Comfort break	
	<b>SESSION NINE - sponsored symposia</b>	

	<p><b>Symposia session 3</b></p> <p><b>Novel Therapies to Manage Cardiovascular Risk</b></p> <p>This promotional symposium is initiated, developed and funded by © Amarin Pharmaceutical Ireland Limited. The speaker faculty will discuss pathways of residual risk and explore novel therapies to manage residual risk to help identify potential patients.</p> <p><i>This symposium is intended for UK Healthcare Professionals only</i></p> <p><b>Sponsored by Amarin</b></p>	<p><b>Dr Peter PENSON</b> Reader in Cardiovascular Pharmacology &amp; Leader of the Clinical Pharmacy and Therapeutics Research Group Liverpool John Moores University</p> <p><b>Dr Adie VILJOEN</b> Consultant Chemical Pathologist Metabolic Medicine &amp; Honorary Consultant Lister Hospital, Stevenage &amp; Cambridge Universities NHS Trust</p>	
10:10 - 10:50			Oculus LT 0.03 - ground floor
10:50 - 11:00	Changeover		
	<p><b>Symposia session 4</b></p> <p><b>Clarifying the appropriate population for Repatha® (evolocumab) with Prof Handrean Soran</b></p> <p><i>This symposium is intended for UK Healthcare Professionals only</i></p> <p><b>Sponsored by Amgen</b></p>		
11:00 - 11:40		<b>Prof Handrean SORAN</b> (Manchester, UK)	Oculus LT 0.03 - ground floor
11:40 - 12:10	Refreshments   Networking   Exhibition		Oculus foyer
	<b>SESSION TEN</b>		
12:10 - 13:10	<p><b>Clinical Lipidology Live</b></p> <p>Live patient case studies and discussion</p>	Facilitator: <b>Dev DATTA + Michaela NUTTALL</b>	Oculus LT 1.05 - 1st floor
13:10 - 13:20	Closing remarks - what one thing has had the biggest impact on lipids in the last 35 years?	<b>Dr Pete GREEN</b> (chair - HEART UK)	